Market Overview

UPDATE: Piper Jaffray Raises PT to $69 on Jazz Pharmaceuticals; Growth Visibility is Solid

Share:
Related JAZZ
BMO Sees Jazz Pharma As 'A Rare Breed In Specialty Pharma'
Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'
Jazz Pharmaceuticals Is One Of The Most Attractive Biotech Stocks (Seeking Alpha)

Piper Jaffray maintained Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Overweight and raises the price target from $65.00 to $69.00.

Piper Jaffray commented, "JAZZ remains our top mid-cap spec pharma pick for 2013, with strong visibility on consistent long-term double-digit EPS growth, high barriers for potential Xyrem generics, all in the context of a 2013 P/E of only 10x. Further, with JAZZ still committed to additional acquisitions of commercial or near-commercial assets, and a strong balance sheet ($387M in cash at YE2012) and potentially more than $400M in operating cash flow generation in 2013, the company is well positioned to execute on a transaction that provides near-term earnings accretion and further revenue diversification in our view."

Jazz Pharmaceuticals closed at $56.83 on Tuesday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Jun 2016BMO CapitalInitiates Coverage onOutperform
Jun 2016Goldman SachsInitiates Coverage onBuy
Jun 2016SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!